Reply: Benefits of statins in healthy elderly subjects: What is the number needed to treat?

Journal of the American College of Cardiology

Volumn 63, Issue 21, 2014, Pages 2303-

  Savarese, Gianluigi ^b   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; DRUG EFFECT; ELDERLY CARE; HEART INFARCTION; HUMAN; LETTER; MEDICAL PARAMETERS; NUMBER NEEDED TO TREAT; PRIORITY JOURNAL; RISK REDUCTION; AGED; FOLLOW UP;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE;

EID: 84901599263     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.02.603     Document Type: Letter

References (4)

1. G. Savarese, A.M. Gotto, and S. Paolillo et al. Benefits of statins in elderly subjects without established cardiovascular disease J Am Coll Cardiol 62 2013 2090 2099
2. H.R. Superko, and S. King 3rd Lipid management to reduce cardiovascular risk: a new strategy is required Circulation 117 2008 560 568
3. D.G. Altman, and P.K. Andersen Calculating the number needed to treat for trials where the outcome is time to an event BMJ 319 1999 1492 1495
4. R.J. Cook, and D.L. Sackett The number needed to treat: a clinically useful measure of treatment effect BMJ 310 1995 452 454